CO5200772A1 - Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes - Google Patents
Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientesInfo
- Publication number
- CO5200772A1 CO5200772A1 CO00065515A CO00065515A CO5200772A1 CO 5200772 A1 CO5200772 A1 CO 5200772A1 CO 00065515 A CO00065515 A CO 00065515A CO 00065515 A CO00065515 A CO 00065515A CO 5200772 A1 CO5200772 A1 CO 5200772A1
- Authority
- CO
- Colombia
- Prior art keywords
- progesterone
- treatment
- prevention
- disorders
- mcphail
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención descubre el uso de mesoprogestinas, una nueva clase de moduladores de receptor de progesterona (MRP), para el tratamiento y la prevención de trastornos ginecológicos benignos hormona-dependientes: a) para el tratamiento de trastornos ginecológicos tales como la endometriosis, los fibromas uterinos, las adherencias peritoneales postoperatorias, la hemorragia disfuncional (metrorragia, menorragia) y la dismenorrea; b) para prevenir trastornos ginecológicos tales como las adherencias peritoneales postoperatorias, hemorragia uterina disfuncional (metrorragia, menorragia) y dismenorrea y c) un método para tratar y prevenir los trastornos antes mencionados en una hembra, preferentemente una hembra humana, que necesite tratamiento o prevención de uno o más de los mencionados trastornos con una cantidad efectiva de mesoprogestina. Las mesoprogestinas se definen como compuestos que disponen de actividad tanto agonística como antagonística en el receptor de progesterona (RP) in vivo. Estabilizan la función de PR en un nivel intermedio entre agonístico y antagonístico. Las progestinas y las antiprogestinas no permiten lograr los mismos estados funcionales. La dosis diaria de mesoprogestina es de 0.5 a 100 mg, preferentemente de 5,0 a 50 mg y más preferentemente de 10 a 25 mg. J867, J912, J956 y J1042 son las mesoprogestinas preferidas de acuerdo con la invención.Figuras 1A y 1BEfectos tipo progesterona (arriba, Figura 1A) yantagonísticos de progesterona (debajo, Figura 1B) de losmoduladores de RP en el útero de conejos inmaduros preparados con estrógeno (prueba de McPhail).Figura lA:Resultado de McPhail<EMI FILE="00065515_1" ID="1" IMF=JPEG >mg/animal/díavehículo - progesterona - RU486 - J867 - J956 - J1042Figura 1BResultado de McPhail<EMI FILE="00065515_2" ID="2" IMF=JPEG >mg/animal/día (dosis de sustancias de prueba + 1,0 mg de progesterona).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38614199A | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5200772A1 true CO5200772A1 (es) | 2002-09-27 |
Family
ID=23524338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00065515A CO5200772A1 (es) | 1999-08-31 | 2000-08-31 | Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1229906B1 (es) |
| JP (1) | JP2003535029A (es) |
| KR (3) | KR100755109B1 (es) |
| AR (1) | AR025457A1 (es) |
| AT (1) | ATE375160T1 (es) |
| AU (1) | AU781840B2 (es) |
| BG (1) | BG65817B1 (es) |
| BR (1) | BR0014161A (es) |
| CA (1) | CA2382580C (es) |
| CO (1) | CO5200772A1 (es) |
| CZ (1) | CZ2002704A3 (es) |
| DE (1) | DE60036723T2 (es) |
| DK (1) | DK1229906T3 (es) |
| EA (1) | EA007854B1 (es) |
| EE (1) | EE05172B1 (es) |
| ES (1) | ES2295050T3 (es) |
| HR (1) | HRP20020267A2 (es) |
| HU (1) | HUP0202429A3 (es) |
| IL (1) | IL148416A0 (es) |
| LT (1) | LT5034B (es) |
| LV (1) | LV12941B (es) |
| ME (1) | MEP13808A (es) |
| MX (1) | MXPA02002191A (es) |
| NO (1) | NO20020999L (es) |
| NZ (1) | NZ517471A (es) |
| PE (1) | PE20010578A1 (es) |
| PL (1) | PL198790B1 (es) |
| PT (1) | PT1229906E (es) |
| RO (1) | RO122179B1 (es) |
| RS (1) | RS50283B (es) |
| SI (1) | SI20852B (es) |
| SK (1) | SK287192B6 (es) |
| UA (1) | UA78184C2 (es) |
| WO (1) | WO2001015679A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003255355A1 (en) * | 2002-08-02 | 2004-02-25 | Schering Aktiengesellschaft | Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy |
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| DE102007011105A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose |
| WO2010147184A1 (ja) * | 2009-06-17 | 2010-12-23 | 国立大学法人熊本大学 | 月経困難症の予防及び／又は治療薬 |
| US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
| JP2022548314A (ja) * | 2019-09-23 | 2022-11-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 妊娠を遷延させるためおよび月経または妊娠の合併症の処置の方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3633244A1 (de) | 1986-09-26 | 1988-03-31 | Schering Ag | Antigestagene zur hemmung der uterinen prostaglandinsynthese |
| DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332284C2 (de) | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5681817A (en) * | 1994-02-04 | 1997-10-28 | The Medical College Of Hampton Roads | Treatment of ovarian estrogen dependent conditions |
| US5576310A (en) * | 1994-09-20 | 1996-11-19 | Jenapharm Gmbh | 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds |
| US5696133A (en) * | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| ES2208699T3 (es) * | 1994-12-22 | 2004-06-16 | Ligand Pharmaceuticals Incorporated | Compuestos y metodos moduladores de receptores de esteroides. |
| KR100370908B1 (ko) | 1995-02-02 | 2003-04-10 | 쉐링 악티엔게젤샤프트 | 기능부전성자궁출혈치료용약제의제조에유용한프로게스테론길항제 |
| DE19604231A1 (de) * | 1996-01-29 | 1997-07-31 | Schering Ag | Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen |
| US6861415B2 (en) * | 1996-05-01 | 2005-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | 21-substituted progesterone derivatives as new antiprogestational agents |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| CA2359562A1 (en) * | 1999-01-14 | 2000-07-20 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| AU4501800A (en) * | 1999-05-04 | 2000-11-17 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
-
2000
- 2000-08-31 ES ES00957914T patent/ES2295050T3/es not_active Expired - Lifetime
- 2000-08-31 KR KR1020027002790A patent/KR100755109B1/ko not_active IP Right Cessation
- 2000-08-31 RS YUP-140/02A patent/RS50283B/sr unknown
- 2000-08-31 WO PCT/US2000/023770 patent/WO2001015679A2/en active IP Right Grant
- 2000-08-31 AR ARP000104538A patent/AR025457A1/es unknown
- 2000-08-31 JP JP2001519893A patent/JP2003535029A/ja active Pending
- 2000-08-31 KR KR1020087016247A patent/KR20080066095A/ko not_active Application Discontinuation
- 2000-08-31 EE EEP200200104A patent/EE05172B1/xx not_active IP Right Cessation
- 2000-08-31 SK SK299-2002A patent/SK287192B6/sk unknown
- 2000-08-31 PL PL353930A patent/PL198790B1/pl not_active IP Right Cessation
- 2000-08-31 IL IL14841600A patent/IL148416A0/xx unknown
- 2000-08-31 ME MEP-138/08A patent/MEP13808A/xx unknown
- 2000-08-31 RO ROA200200229A patent/RO122179B1/ro unknown
- 2000-08-31 PT PT00957914T patent/PT1229906E/pt unknown
- 2000-08-31 DE DE60036723T patent/DE60036723T2/de not_active Expired - Lifetime
- 2000-08-31 CO CO00065515A patent/CO5200772A1/es not_active Application Discontinuation
- 2000-08-31 UA UA2002032430A patent/UA78184C2/uk unknown
- 2000-08-31 CZ CZ2002704A patent/CZ2002704A3/cs unknown
- 2000-08-31 EA EA200200282A patent/EA007854B1/ru not_active IP Right Cessation
- 2000-08-31 CA CA002382580A patent/CA2382580C/en not_active Expired - Lifetime
- 2000-08-31 EP EP00957914A patent/EP1229906B1/en not_active Expired - Lifetime
- 2000-08-31 DK DK00957914T patent/DK1229906T3/da active
- 2000-08-31 PE PE2000000893A patent/PE20010578A1/es not_active Application Discontinuation
- 2000-08-31 HU HU0202429A patent/HUP0202429A3/hu unknown
- 2000-08-31 AT AT00957914T patent/ATE375160T1/de not_active IP Right Cessation
- 2000-08-31 KR KR1020077011455A patent/KR100864547B1/ko not_active IP Right Cessation
- 2000-08-31 BR BR0014161-5A patent/BR0014161A/pt not_active Application Discontinuation
- 2000-08-31 NZ NZ517471A patent/NZ517471A/en unknown
- 2000-08-31 AU AU69466/00A patent/AU781840B2/en not_active Ceased
- 2000-08-31 SI SI200020042A patent/SI20852B/sl not_active IP Right Cessation
-
2002
- 2002-02-26 BG BG106442A patent/BG65817B1/bg unknown
- 2002-02-28 NO NO20020999A patent/NO20020999L/no not_active Application Discontinuation
- 2002-02-28 MX MXPA02002191A patent/MXPA02002191A/es active IP Right Grant
- 2002-03-21 LT LT2002031A patent/LT5034B/lt not_active IP Right Cessation
- 2002-03-28 LV LVP-02-53A patent/LV12941B/lv unknown
- 2002-03-28 HR HR20020267A patent/HRP20020267A2/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR011480A1 (es) | ACIL-ANILIDAS SUSTITUIDAS CON RADICALES (HETERO) CICLICOS, NO ESTEROIDALES, CON ACTIVIDAD GESTÁGENA Y ANDRoGENA MIXTA. | |
| ES2281551T3 (es) | Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas. | |
| EP1390041B1 (en) | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception | |
| CO5200772A1 (es) | Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes | |
| HUP0300335A2 (hu) | 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| PT792152E (pt) | Metodos de contracepcao | |
| MXPA05005897A (es) | Derivados tetraciclicos novedosos, que contienen heteroatomos, como moduladores selectivos del receptor de estrogeno. | |
| CR7611A (es) | Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona | |
| ECSP055530A (es) | Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva | |
| CO5190694A1 (es) | Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos | |
| EA200100828A1 (ru) | 16-гидроксиэстратриены в качестве эстрогенов избирательного действия | |
| CO5200773A1 (es) | Mesoprogestinas (moduladores de receptores para progestero- na) como componente de composiciones utilizadas para la terapia de sustitucion hormonal (trh) | |
| WO2002056903A3 (en) | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators | |
| Cavaco-Goncalves et al. | Increased cervical electrical activity during oestrus in progestagen treated ewes: Possible role in sperm transport | |
| Hahn et al. | The pharmacological profile of norgestimate, a new orally active progestin | |
| SI1173210T1 (en) | Contraceptive compositions containing antiprogestinic and progestinic | |
| UY26665A1 (es) | Estratrienos sustituidos como estrógenos selectivamente activos | |
| ŁKARDA | Detection of estrogenicity by bioassay on the mouse mammary gland in vivo | |
| Garcia et al. | Characteristics of ejaculated rat semen after lesion of scrotal nerves | |
| CZ205095A3 (en) | Inhibition process of ripening and/or fertilization of oocytes and a set for making thereof | |
| Peplow et al. | An intrauterine silastic system for the sustained release of indomethacin | |
| Van der Schoot et al. | Interactions between oestradiol and the progesterone antagonist RU-486 in establishing and maintaining female rats' sexual responsiveness: central versus peripheral effects | |
| Dalterio et al. | Effects of Δ9-THC and castration on behavior and plasma hormone levels in male mice | |
| Nunes et al. | Monitoring of progesterone and estradiol fecal metabolites during estrous cycle in sows. | |
| PE20030411A1 (es) | DERIVADOS 8ß-SUSTITUIDOS DE 11ß-FENIL Y 11ß-HEXIL-ESTRA-1,3,5(10)-TRIENO QUE TIENEN AFINIDAD POR RECEPTORES DE ESTROGENO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |